Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Exosomes

Also known as: exosome, extracellular vesicles, EVs, biosomes

Extracellular vesicles are lipid-bilayer particles released by cells that cannot replicate. “Exosome” names those of demonstrated endosomal origin, not a size class. In professional skincare, EV-containing preparations are applied topically after procedures that open the skin.

Evidence status

Emerging

Vesicle biology is well established. The aesthetic clinical evidence cited here is a single uncontrolled, sponsor-run report of one named product, with no comparator arm and participant yes/no outcomes. It cannot isolate an EV effect, and it does not transfer to any other preparation.

What they actually are#

An extracellular vesicle is a particle released from a cell, bounded by a lipid bilayer, that cannot replicate on its own.[2]They are not cells, and they are not alive. Think of them as sealed envelopes carrying instructions — proteins, lipids, messenger RNA and microRNA — from the cell that produced them to the cells that receive them.

Why the word “exosome” is doing more work than it should

“Exosome” is not a size class. It is a biogenesis term: it names vesicles that come from the endosomal pathway. The international consensus on EV reporting discourages biogenesis terms unless subcellular origin can actually be demonstrated for the specific source and condition, and states plainly that small EV and exosome are not synonyms.[2] A particle is not an exosome because it measures 90 nanometres.

The most-cited review of the field describes exosomes as vesicles of roughly 40 to 160 nanometres, averaging about 100, with an endosomal origin— the origin is part of the definition.[1] Unless a supplier can show endosomal origin, the accurate words are small EV or EV-containing preparation. That is not pedantry: it is the difference between describing what is in the bottle and repeating what the label says.

Nor are these particles one category. Native extracellular vesicles, artificial cell-derived vesicles produced by deliberately disrupting cells, and synthetic vesicles built de novo from molecular components are distinct things.[2] Evidence for one is not evidence for another.

What they are not

Exosome products do not contain live stem cells, and reputable suppliers do not claim they do. A preparation described as “stem cell derived” means the vesicles were harvested from a cell culture — the cells themselves are not in the bottle. This distinction matters both scientifically and for how you describe treatments to clients.

The science, and what the one study shows#

Every nucleated cell releases extracellular vesicles, and their role in intercellular signalling is well established across oncology, immunology and regenerative medicine as well as aesthetics.[2] That much is not in dispute. What is in dispute is what a bottle of them does to a face.

The proposed mechanism

The wound-healing cascade progresses through haemostasis, inflammation, proliferation and remodelling. Fibroblast activity during the proliferative phase is what ultimately produces new collagen, and fibroblasts are regulated by signalling molecules in their local environment. Exosome preparations are proposed to influence that environment. Proposed is the operative word: the mechanism is the argument for the product, not evidence produced by it.

The one human report, described honestly

One uncontrolled, sponsor-run report followed more than 100 people given three sessions of standard microneedling plusa named human umbilical-cord Wharton’s-jelly MSC-derived product, at four- to six-week intervals. There was no microneedling-only arm and no vehicle arm. Outcomes were participant yes/no questionnaire responses, and the photographs and questionnaires were shared with the sponsor for analysis.[3]

What it shows is that participants reported improvement after the combined protocol. What it cannot show is how much of that came from the product rather than from the microneedling — there is no arm that would let anyone separate the two. And it did not measure collagen or fibroblasts at all: increased fibroblast proliferation and collagen synthesis appear in the paper as the authors’ proposed mechanism, not as a result.[3]

The provenance belongs in the same sentence as the finding. The lead author is Chief Medical Officer of the product’s manufacturer, four of the six authors held positions in the company group, and the paper discloses consultative or financial relationships between several investigators and that group. None of that makes the observation false. It does mean it is a company report of its own product, and it should be read as one.

Where the material comes from#

The single most important thing a UK practitioner needs to establish about an exosome product is what it was harvested from — and the industry’s favourite framing of that question is wrong.

“Lab-made” is not the opposite of human-derived

Suppliers routinely offer “lab-made” or “bio-identical” as the compliant alternative to human-derived material. Neither is a recognised scientific or regulatory category, and the framing conceals the actual issue: vesicles harvested from cultured human cells are still products of human origin. The product in the one human report cited on this page was itself grown in laboratory culture — from human umbilical-cord Wharton’s-jelly cells.[2, 3] “Made in a lab” tells you where it was produced, not what it came from.

The question to actually ask

Ask what species and tissue the source cells came from, in writing. Plant-derived, bacterial, other mammalian-cell-derived, engineered cell-derived and fully synthetic preparations are different categories with different evidence and different legal positions.[2]A supplier who answers “bio-identical” has not answered.

This is not theoretical. A November 2025 undercover investigation contacted 50 UK clinics offering exosome treatments; 40 disclosed the brand they used, most of them plant- or salmon-derived, and almost a quarter admitted to products derived from human stem cells, naming umbilical cords and fat cells.[8]

UK regulatory position#

Injection is not a cosmetic route

In both Great Britain and Northern Ireland, products intended to be ingested, inhaled, injected or implanted are not classified as cosmetic products at all.[4, 5] That settles the category question, and it settles it the same way in both jurisdictions.

It does not, by itself, settle what an injectable EV preparation is. Whether a given product is a medicinal product is assessed for that product, from its claims, its presentation to the public, the pharmacological, metabolic or immunological properties of its ingredients, and its intended purpose.[7] “Not a cosmetic” and “therefore a medicine” are two different findings.

You will read everywhere — on clinic sites, in trade guidance, in insurer briefings — that the MHRA regards injected exosomes as medicinal products. We searched for the record behind that sentence and could not find one: no published determination, safety communication or authorisation dealing specifically with exosome preparations in aesthetics.[no source found] It may well be the MHRA’s position. We are not going to assert it as a finding when we cannot show you the record.

Human-origin material in cosmetics

Annex II of the Cosmetics Regulation is the list of substances prohibited in cosmetic products. Reference number 416 is “cells, tissues or products of human origin”. Great Britain applies the assimilated Regulation; Northern Ireland applies EU Regulation 1223/2009 itself, a separate regime with its own Responsible Person and notification requirements.[4, 5, 6] The prohibition is in both.

Topical is not the same as authorised

Applying a product topically does not make it compliant. A topical cosmetic still has to meet the composition, Responsible Person, safety assessment, product information file, notification, labelling and claims requirements of the regime where it is placed on the market.[4, 5] “We only use it topically” answers the route question and nothing else.

This is a developing area. Verify the current position before making any claim in marketing or consultation, and record the product’s source and intended use in your treatment notes.

In clinical practice#

What the evidence licenses you to do

The cited human report evaluated one named product applied after standard microneedling. It does not establish timing comparisons, use after RF microneedling or laser, use beneath an occlusive, reduced downtime, an optimal interval, or when a result should appear.[3] Follow the lawful intended use and the instructions for the exact product and the exact procedure in front of you. Do not carry this report across to another product or another device.

We removed a sequencing protocol, a downtime claim and a pricing strategy from this page in August 2026. They read well and several of them are probably what most clinics do. None of them had a source, and operating instructions on a page that claims claim-level accountability need one.

The consultation

Clients increasingly arrive already knowing the word “exosomes”, which changes the job: usually you are setting expectations rather than introducing a concept. The most useful thing you can tell them is the truth — that the biology is real, that the aesthetic evidence is one uncontrolled company study of one product, and that nobody has yet measured how much the product adds to the procedure it accompanies.

Safety and contraindications#

Exosome application inherits the contraindications of the procedure it accompanies, so screening for microneedling or laser applies in full. Beyond that:

  • Product provenance. Establish the species and tissue the source cells came from, and whether the product is lawfully placed on the market for the use you intend.
  • Manufacturer instructions. Follow the storage, reconstitution and handling instructions for that exact product. There is no generic exosome protocol to fall back on.
  • A deliberately breached barrier. Applying a biologically active preparation to skin you have just opened raises the stakes on sterility and on provenance together. Use a single-use, sealed presentation and an aseptic technique, and do not apply anything to open channels whose composition and lawful use you cannot account for.
  • Claims. Do not describe topical exosome application as a medical treatment, and do not imply an authorisation the product does not hold.

What remains uncertain#

Being straight about the limits of the evidence is more useful to a practitioner than overstating it, so:

  • The added effect is not established at all. The one cited human report had no comparator arm, so it cannot say how much difference the product made over microneedling alone.[3]
  • Collagen has not been measured. The collagen story is a mechanism, not a finding.[3]
  • Products are not interchangeable. Source species and tissue, vesicle content, isolation method and stability vary enormously between suppliers, and native EVs, cell-derived mimetics and synthetic particles are not even the same category of thing.[2] Evidence for one product does not transfer to another.
  • Penetration is inferred, not measured. The premise that meaningful quantities reach the viable epidermis and dermis through microneedling channels is reasonable, but is not something routine clinical practice can verify.
  • The regulatory picture is moving— and part of it is not publicly documented at all, as the missing MHRA record above shows.[no source found]

Frequently asked questions#

Are exosomes legal in the UK?

Topical EV-containing products are used in UK clinics. Injection is not a cosmetic route in either Great Britain or Northern Ireland,[4, 5] and Annex II entry 416 prohibits cells, tissues or products of human origin in cosmetic products.[4, 5, 6] Whether a specific injectable preparation is a medicinal product is a product-by-product assessment.[7]

Is a “lab-made” or “bio-identical” exosome compliant?

Those are marketing words, not regulatory categories, and they do not answer the question. Vesicles cultured from human cells are still of human origin.[2, 3] Ask what species and tissue the source cells came from.

Do exosomes contain stem cells?

No. They are vesicles released by cells, and a vesicle cannot replicate.[2] A product described as stem cell derived means the vesicles came from a stem cell culture; no living cells are present.

Can exosomes be used without microneedling?

The only human report cited here applied the product after standard microneedling, so it says nothing either way about use on intact skin.[3] The delivery rationale for using them after a procedure is a reasonable argument; it has not been tested against the alternative.

How do exosomes differ from polynucleotides?

Both sit under the regenerative umbrella but differ fundamentally. Polynucleotides are purified DNA fragments, usually injected. EV preparations are vesicles, applied topically in UK practice.

How soon do clients see results?

Nobody knows, and we are not going to invent a number. The one cited report assessed participants four to six weeks after their third session and asked them yes/no questions; it did not compare time points or measure the course of a response.[3] Claims about faster settling or shorter downtime have no source behind them.[3]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.Tier 4Supports: General extracellular-vesicle biology and the role of vesicles in intercellular signalling. Describes exosomes as EVs 'with a size range of ~40 to 160 nm (average ~100 nm) in diameter with an endosomal origin'. NOTE: the article reports no systematic search or selection method, so it is a narrative review, not a systematic one. Use for background biology only.Funding / interest: Supported by research funds from MD Anderson Cancer Center and by NCI grants RO1 CA213233, RO1 CA195733 and CA 231465. Declared: 'MD Anderson Cancer Center and R.K. hold patents in the area of exosome biology and are licensed to Codiak Biosciences, Inc. MD Anderson Cancer Center and R.K. are stock equity holders in Codiak Biosciences, Inc. R.K. is a consultant and scientific adviser for Codiak Biosciences, Inc. V.S.L. is a paid consultant for Codiak Biosciences, Inc.'
  2. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. Journal of Extracellular Vesicles. 2024;13(2):e12404.Tier 4Supports: The consensus position of the International Society for Extracellular Vesicles on nomenclature. Defines an extracellular vesicle as a particle released from a cell, delimited by a lipid bilayer, that cannot replicate on its own. States that 'biogenesis terms are discouraged unless subcellular origin can be demonstrated for the specific EV source and condition', and that 'sEV (for small EV) and exosome are not synonymous'. Separately defines artificial cell-derived vesicles (EV mimetics produced under induced cell disruption, such as extrusion) and synthetic vesicles (EV mimetics synthesised de novo from molecular components, or hybrids).
  3. Cicchetti C, Mazzeo M, Heke M, Crowley M, Crowley E, Ntonos A. Topical Wharton's Jelly MSC-derived Age Zero exosome treatments after micro-needling for skin rejuvenation. Journal of Cosmetic Dermatology. 2024.Tier 3Supports: An uncontrolled report of more than 100 participants given three sessions of microneedling (SkinPen Precision) plus a named human umbilical-cord Wharton's-jelly MSC-derived product at four- to six-week intervals, assessed four to six weeks after the last session. THERE WAS NO MICRONEEDLING-ONLY AND NO VEHICLE ARM. Outcomes were participant yes/no questionnaire responses; photographs and questionnaires were shared with the sponsor for analysis. Collagen and fibroblasts were not measured — increased fibroblast proliferation and collagen synthesis appear only as the authors' proposed mechanism. Supports only that participants reported improvement after the combined protocol, for that exact product and protocol.Funding / interest: Sponsor-run and product-owner-authored. States 'the authors received no specific funding for this work', which does not describe the study's provenance: the lead author is Chief Medical Officer of Regenerelle, the product's manufacturer, and the paper discloses consultative or financial relationships between several investigators and the affiliated company group. Four of the six authors held positions at the company group; one investigator was external.
  4. Office for Product Safety and Standards. Regulation 20091223 and the Cosmetic Products Enforcement Regulations 2013: Great Britain. GOV.UK.Tier 1Supports: The law applying in Great Britain is Regulation (EC) No 1223/2009 as amended by the Product Safety and Metrology etc. (Amendment etc.) (EU Exit) Regulations 2019. A cosmetic product's field of application is 'the epidermis, the hair system, the nails, the lips, the external genital organs, the teeth, the mucous membranes of the oral cavity'. States: 'Products that are intended to be ingested, inhaled, injected or implanted are not classified as cosmetic products.' Annex II lists ingredients prohibited in all cosmetics.
  5. Office for Product Safety and Standards. Regulation 20091223 and the Cosmetic Products Enforcement Regulations 2013: Northern Ireland. GOV.UK.Tier 1Supports: Northern Ireland applies EU Regulation (EC) No 1223/2009 itself, not the Great Britain version — a separate regime with its own Responsible Person and notification requirements (CPNP rather than the GB service). The same exclusion applies: 'Products that are intended to be ingested, inhaled, injected or implanted are not classified as cosmetic products.'
  6. Regulation (EC) No 1223/2009 on cosmetic products, Annex II — list of substances prohibited in cosmetic products, reference number 416. legislation.gov.uk (assimilated law as it applies in Great Britain).Tier 1Supports: Annex II reference number 416 is 'Cells, tissues or products of human origin'. Annex II is the list of substances prohibited in cosmetic products.
  7. Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. GOV.UK. Last updated 2 July 2026.Tier 1Supports: How the MHRA assesses whether a product is a medicinal product: 'the claims about what the product does (explicit and implicit)'; 'how it is presented to the public through labelling, packaging, promotional literature, advertisements, websites, social media and customer reviews'; 'the pharmacological, metabolic or immunological properties of the ingredients'; 'the primary intended purpose of the product or the manner in which it would be used by consumers'; and whether similar licensed products exist. The assessment is of the individual product.
  8. Aesthetics journal. Investigation reports human-derived exosomes in UK clinics. 17 November 2025, reporting a 5 News undercover investigation.Tier 4Supports: 5 News contacted 50 clinics across Bristol, Cardiff, Glasgow, London and Liverpool. Forty of the 50 disclosed the exosome brand used; most were plant- or salmon-derived. Almost a quarter admitted to products derived from human stem cells, naming umbilical cords and fat cells as the tissue sources. A Department for Business and Trade spokesperson is quoted: 'Cosmetics containing exosomes from humans are banned in the UK. Although we have not seen an increase in reports of non-compliance, we urge anyone with concerns to contact their local Trading Standards department or Citizens Advice.' A trade report of a broadcast investigation, not a regulatory record or a prevalence study.